17 Innovative Biopharma Companies Secure Funding, with 7 from China | Weekly Financing Roundup

Nov 25, 2024 17:08 CST Updated 17:08

Enveda

Small Molecule Therapy Developer

ATB Therapeutics

Novel Antibody Therapy Researcher

BreezeBio

Gene Therapy Developer

▎Edited by the WuXi AppTec content team

According to incomplete statistics from Innovation Radar, last week (November 18 to November 24), the global health and wellness fieldA total of 34 financing events were disclosed, with a total amount exceeding 4.2 billion yuan.In terms of the amount, there were 14 financings of 100 million yuan or more. According to the disclosed financing rounds, there were 20 early-stage financings (before Series B) and 11 mid-to-late stage financings (Series B and onwards). A total of 17 companies in the biopharmaceutical field received financing, involving drug types including innovative small molecules, antibody drugs, gene drugs, etc., of which seven are from China.

#01

Enveda Completes $130 Million Series C Financing

Keywords: Small Molecule Drugs

Latest Financing:$130 Million Series C

This round of investment institutions: Baillie Gifford, Cresset Partners, Dimension Capital, FPV Ventures, etc.

November 23Enveda Biosciences, Inc. today announced the completion of a $130 million oversubscribed Series C financing, bringing the company's total funding to $360 million. This new capital will help advance multiple pipeline programs into clinical development in 2025 and 2026.The R&D pipeline includes 10 candidate development projects and multiple discovery projects.Covering immunology and inflammation, obesity, fibrosis, and neurosensory indications, with "first-in-class" and "best-in-class" potential. Enveda is committed to integrating artificial intelligence, mass spectrometry, and high-throughput biological experiments to systematically analyze the chemical structures and functions of natural compounds. Within just four years, Enveda's platform has characterized the structures and functions of more than one million natural products, building a vast database of known natural compounds.

#02

ATB Therapeutics Completes €54 Million Series A Financing

Keyword: Antibody Drug

Latest Financing:€54 million AWheel

This round of investment institutions: SFPIM, EQT Life Sciences, Fondation Fournier-Majoie, Luxembourg Business Angel Network (LBAN), etc.

News on November 18: ATB Therapeutics successfully completed a 54 million euro Series A financing. The company is aA company focused on developing potential first-in-class biopharmaceuticals with a novel cell-killing mechanism(Including enzyme functions) are incorporated into targeted antibodies. This novel antibody structure integrates multiple cytotoxic and targeting components, significantly enhancing the efficacy and safety of drugs compared to traditional conjugates. With the help of ATBioFarm technology, these complex biologics can be produced in a scalable single-step process, expected to achieve significant progress in various therapeutic applications. This funding will help ATB enhance the ATBioFarm platform and accelerate the development of its unique weaponized antibodies for oncology and immunology applications.

#03

GenEdit Completes $35 Million Series B Financing

Keywords: Gene Medicine

Latest Financing: $35 Million Series BWheel

This round of investment institutions: ACVC, DSC Investment, Dayli Partners, IMM Investment, K2 Investment, KDB Silicon Valley, Kiwoom Investment, etc.

News on November 20: Gene drug development biotechnologyGenEdit Announces Completion of $35 Million Series B Financing to Develop Drugs for Immune Diseases. GenEdit's NanoGalaxy Platform IncludesA large number of chemically diverse hydrophilic nanoparticles(HNPs), each with unique properties, are suitable for targeting different tissues and cell types while capable of carrying various types of genetic medicine payloads. GenEdit has successfully delivered siRNA, mRNA, and gene-editing systems to the nervous system, immune system, and other extrahepatic systems in vivo. The company is actively advancing research across multiple therapeutic areas through internal R&D and collaborative projects.

#04

Valora Therapeutics Completes $30 Million Seed Financing

Keyword: Immunotherapy

Latest Financing: $30 Million Seed Round

This round of investment institutions: AVALON-BIOVENTURES, Alexandria Venture Investments, Bregua Corporation, Correlation Ventures, TigerGene

November 21Valora Therapeutics Announces Successful Completion of $30 Million Seed Financing Round, the Company is Committed toLeveraging Its Glyco-Immune Checkpoint Technology Platform to Transform Immunotherapy DevelopmentValora’s AbLec platform (antibody-lectin chimera) is expected to provide a new perspective for restoring the normal function of the immune system. By precisely targeting specific sugar molecules on the cell surface, the AbLec platform can modulate glyco-immune checkpoints, a crucial regulatory mechanism of the body's immune response. This innovative approach holds significant potential for developing potential “first-in-class” and “best-in-class” therapies in the fields of oncology, autoimmune diseases, and other therapeutic areas.

#05

BreezeBio Completes Financing Round Worth Hundreds of Millions

Keyword: Immunotherapy

Latest Financing:Hundreds of Millions of RMB Unknown Round

This Round's Investment Institutions: PICC Capital Equity Investment, QingSong Capital

On November 20, Breeze Bio announced the completion of a new round of financing worth hundreds of millions of yuan. Established in 2018, Breeze Bio is committed to developing next-generation specific immunotherapies for allergic and autoimmune diseases. According to the company's press release,The company has a wholly-owned subsidiary in Europe that integrates production, research, and sales, with dozens of commercialized products.BreezeBio is actively expanding its global market and promoting the clinical development and commercialization in China of innovative allergy immunotherapy products already launched in Europe. Meanwhile, it has rapidly built a pipeline for the research and development of allergy and autoimmune disease indications based on new technology platforms. Among them, several pipelines, such as grass pollen allergy and Graves' disease, have entered Phase 2 and Phase 3 clinical study stages in different countries around the world.

Readers, please star ⭐Chuangjianhui to receive updates第一时间.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article was compiled and edited by the content team of WuXi AppTec based on publicly available information. Individuals are welcome to share it on their social media platforms, but unauthorized reposting or reproduction by media or institutions in any form to other platforms is strictly prohibited. For authorization to repost, please contact:"Chuangjian Hui"Contact us by leaving a message on our WeChat Official Account.

More Data Content Recommended

Click "InSee", Sharing Chuangjianhui Health New Trends